Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients
Open Access
- 1 October 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 21 (2), e62-e75
- https://doi.org/10.1016/j.clcc.2021.09.008
Abstract
No abstract availableKeywords
Other Versions
Funding Information
- Louisiana State University Health Sciences Center
This publication has 35 references indexed in Scilit:
- Predictive and Prognostic Roles ofBRAFMutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803Clinical Cancer Research, 2012
- Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practiceBreast Cancer Research and Treatment, 2012
- Chemotherapy-induced peripheral neurotoxicityNature Reviews Neurology, 2010
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon CancerJournal of Clinical Oncology, 2010
- Identification of 12 or more lymph nodes in resected colon cancer specimens as an indicator of quality performanceCancer, 2009
- Choice and Interpretation of Statistical Tests Used When Competing Risks Are PresentJournal of Clinical Oncology, 2008
- Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5‐fluorouracil/leucovorin plus or minus oxaliplatinCancer, 2007
- Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patientsBritish Journal of Cancer, 2007
- Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the ElderlyJournal of Clinical Oncology, 2006
- Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon CancerThe New England Journal of Medicine, 2004